Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.

ABSTRACT: Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function

SUBMITTER: Guilloux JP 

PROVIDER: S-EPMC4289958 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature